Confidential Corporate Presentation Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and ...

Financial Data and Key Metrics Changes - Gossamer Bio ended Q1 2019 with $492.5 million in cash and cash equivalents, which included an $11 million interest in securities receivable [36] - The company reported a net loss of $32.6 million for the quarter, equating to $0.90 per share [37] - Research and development expenses were approximately $25 million, reflecting a ramp-up for GB001, GB002, and GB004 [37] Business Line Data and Key Metrics Changes - GB001, an oral DP2 antagonist, is in a Phase 2b trial for eosinophilic asthma, with an interim analysis expected in the first half of 2020 [7][9] - GB002, an inhaled PDGFR inhibitor for Pulmonary Arterial Hypertension (PAH), completed Phase 1 safety studies and is set to begin Phase 1b trials later in Q2 2019 [21][22] - GB004, an oral HIF-1 stabilizer for Inflammatory Bowel Disease, has begun a Phase 1b trial in patients with active mild to moderate ulcerative colitis [26][27] - GB1275, an oral CD11b modulator for cancer treatment, is expected to enter Phase 1/2 studies in advanced solid tumors in the second half of 2019 [29][30] Market Data and Key Metrics Changes - The company aims to position GB001 in the moderate persistent asthma market, targeting patients who are not adequately controlled on current therapies [77][80] - Gossamer Bio is focusing on chronic rhinosinusitis and chronic spontaneous urticaria, with no significant competitors in the oral treatment space [58][66] Company Strategy and Development Direction - Gossamer Bio is focused on becoming a leader in immunology, inflammation, and oncology, with multiple data readouts expected in 2020 [6] - The company is actively pursuing business development opportunities in late-stage research programs that align with its existing pipeline [94][95] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the momentum generated in developing multiple product candidates that could significantly improve patient lives [39] - The strong financial position allows the company to continue advancing its scientific efforts [39] Other Important Information - Gossamer Bio closed its IPO in February 2019, raising over $291 million in net proceeds, and secured a $150 million debt facility [34][35] - The company will host a fireside chat at the Bank of America/Merrill Lynch Healthcare Conference [33] Q&A Session Summary Question: What is the significance of Novartis' Phase 3 trial results for GB001? - Management anticipates that positive results from Novartis' trials would validate the mechanism of DP2 antagonism, benefiting GB001 [45][49] Question: What were the findings from the Phase 1 trial for GB002? - The Phase 1 trial showed a favorable PK profile with rapid absorption and fast clearance, confirming the inhaled formulation's tolerability [50][53] Question: What biomarkers will be evaluated in the Phase 2 trial for GB002? - Key biomarkers include NT-proBNP levels and imaging measures like cardiac MRIs to assess right heart function [86][87] Question: How will GB004's clinical activity be measured? - Clinical activity will be assessed through HIF-1 alpha levels and histopathology indices in ulcerative colitis patients [90][91] Question: What is the company's approach to market positioning for GB001? - The company is focusing on the moderate persistent asthma market, targeting patients who are not adequately controlled by existing therapies [77][80]